Fulgent Genetics, Inc.(FLGT) stock price and fundamentals

Medical - Diagnostics & Research · El Monte, CA

$21.31-1.14 (-5.08%)

Delayed quote: Oct 6, 2026, 10:34 AM EDT

About Fulgent Genetics, Inc.

Fulgent Genetics, Inc., together with its affiliated companies, offers a comprehensive suite of COVID-19, molecular diagnostic, and genetic testing services to healthcare providers and individuals globally. Their diverse array of genetic tests covers a wide range of applications, including extensive oncology panels and solid tumor molecular profiling for cancer identification, Beacon carrier screening for inherited conditions, and specialized rapid whole genome testing for critically ill infants in NICU and PICU units. Other offerings include a newborn genetic analysis panel, a front-line test to sequence ataxia-related variants, and patient-initiated genetic testing via Picture Genetics. They also provide comprehensive whole exome, clinical exome, whole genome, mutation, and repeat expansion testing, alongside research service tests. For COVID-19, the company delivers next-generation sequencing, reverse transcription polymerase chain reaction (RT-PCR), and antigen-based diagnostic solutions for SARS-CoV-2. Beyond genetic and COVID-19 diagnostics, Fulgent Genetics performs advanced laboratory analyses such as flow cytometry for cell analysis and malignancy monitoring, fluorescence in-situ hybridization (FISH) for specific DNA sequence detection, immunohistochemistry (IHC) to visualize cellular antigens, and cytogenetics for assessing chromosomal anomalies, in addition to molecular testing for both hematopoietic and solid tumors. Their clientele is broad, including insurance companies, hospitals, medical institutions, fellow laboratories, government agencies, payors, municipal bodies, major corporations, and direct patients. The company has formed a strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. Founded in 2011 and headquartered in Temple City, California, the company was previously known as Fulgent Diagnostics, Inc. before adopting its current name in August 2016.

El Monte, CA

1,315 employees

www.fulgentgenetics.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Ming Hsieh

View full financials

Stock	Market Cap	Close Price	Price Change	TTM Total Return	5Y CAGR	10Y CAGR	Compare
1FLGT	$605.22M	$21.31	-5.08%	-1.44%	-22.38%	+8.90%	N/A
2ANGO	$612.34M	$14.81	-4.67%	+33.32%	-10.80%	-0.58%	vs FLGT
3IRWD	$596.72M	$3.63	-0.68%	+134.52%	-22.82%	-13.70%	vs FLGT
4CLYM	$624.17M	$10.90	-1.36%	+453.52%	N/A	N/A	vs FLGT
5KIDS	$580.22M	$22.59	-1.31%	+21.83%	-18.40%	N/A	vs FLGT
6AURA	$635.62M	$6.14	-1.21%	+2.80%	N/A	N/A	vs FLGT

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$-0.65	$-0.65	$-0.65	1
Quarter ending Dec 2026	$-0.69	$-0.69	$-0.69	1
Quarter ending Mar 2027	$-0.50	$-0.50	$-0.50	1
Quarter ending Jun 2027	$-0.27	$-0.27	$-0.27	1

Period	Low	Avg	High	# Analysts
FY 2026	$-2.27	$-2.27	$-2.27	1
FY 2027	$-1.38	$-1.38	$-1.38	1

Period	Low	Avg	High	# Analysts
Quarter ending Sep 2026	$86.30M	$86.30M	$86.30M	1
Quarter ending Dec 2026	$88.90M	$88.90M	$88.90M	1
Quarter ending Mar 2027	$91.50M	$91.50M	$91.50M	1
Quarter ending Jun 2027	$94.70M	$94.70M	$94.70M	1

FY 2026	$331.70M	$331.70M	$331.70M	1
FY 2027	$382.70M	$382.70M	$382.70M	1

Fulgent Genetics, Inc.(FLGT) stock price and fundamentals

Valuation

Yields

FLGT Price Chart

Business at a glance

FLGT Key Metrics

Total Return CAGR

FLGT Fundamental Charts

Revenue CAGR

FLGT Selected Revenue Disclosures

Product / business disclosures (FY 2025)

Geographic disclosures (FY 2025)

FLGT Earnings Preview

Similar-Size Sector Stocks

FLGT Competitors' Key Metrics

FLGT Charts

Valuation Charts

Performance Charts

Dividend Charts

CAGR Charts

Financial Statement Charts

Other Charts

FLGT Analyst Ratings

FLGT Analyst Estimates

Earnings Per Share (EPS) Estimates

Revenue Estimates